Nine clinical trials starting soon in health disparities and/or led by underserved researchers
These Diversity, Equity & Inclusion trials, funded by Cures Within Reach, include support from community-based organizations
CHICAGO - May 5, 2022 - PRLog -- Cures Within Reach (www.cureswithinreach.org)
Five of the nine are health disparities trials that include engagement with health and/or social services-related community-based organizations that are trusted and already engaged with communities of color to support the trials. These trials also seek to engage and educate prospective participants, help to reduce both mistrust and distrust, and share the opportunity to improve the health and healthcare of communities of color. This community engagement is an integral part of these clinical trials.
Respected research institutions across the U.S. will start the following clinical trials soon, all led by underrepresented researchers and four within health disparities:
Cures Within Reach's DEI trials are supported by donors and sponsors that include the Searle Funds at The Chicago Community Trust, Takeda Pharmaceuticals' R&D Center for Health Equity and Patient Affairs, Burroughs Wellcome Fund and others.
"Burroughs Wellcome Fund (BWF) is excited to partner with Cures Within Reach to address health disparities. By engaging community-based organizations who are actively working with the communities affected by health inequities, innovative new therapies are more accessible to a wider swath of patients," said BWF Program Officer Dr. Kelly Rose. "Involving a diverse patient population in clinical trials can lead to a data set that more accurately represents how the intervention will work in the general public and lead to more robust therapies."
"Our funding partners represent a variety of interests, but with aligned goals to address health disparities,"
Cures Within Reach focuses on first-in-human or proof-of-concept clinical repurposing trials that catalyze the follow-on funding needed to continue the research – building evidence for publication and follow-on trials allowing clinicians to make their own decisions with their patients (called off-label use), or for regulatory approval by the FDA or other agencies. In addition to this DEI initiative, other 2022 initiatives at Cures Within Reach include impacting Veterans' Issues and Pediatrics, as well as several disease-specific efforts.
"There is a very real and pressing need to diversify the clinical trial ecosystem to include traditionally under-represented patients and researchers, particularly those from communities of color," says Dr. Chris Reddick, Vice President and Head of R&D Health Equity at Takeda. "We are working with partners like Cures Within Reach to empower clinical researchers to address the health inequities that matter most to their communities and ultimately to provide better care for their patients long-term."
Back To Index | PR Log at - PRLog.org/12916026